company background image
NEO logo

NeoGenomics NasdaqCM:NEO Stock Report

Last Price

US$16.53

Market Cap

US$2.1b

7D

-8.0%

1Y

-20.3%

Updated

23 Dec, 2024

Data

Company Financials +

NEO Stock Overview

Operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. More details

NEO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

NeoGenomics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for NeoGenomics
Historical stock prices
Current Share PriceUS$16.53
52 Week HighUS$20.94
52 Week LowUS$12.77
Beta1.23
1 Month Change0.85%
3 Month Change4.62%
1 Year Change-20.26%
3 Year Change-50.14%
5 Year Change-43.22%
Change since IPO535.77%

Recent News & Updates

NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Nov 23
NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Oct 16
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Recent updates

NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Nov 23
NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Oct 16
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

Aug 01
Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Jul 15
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Mar 30
Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Dec 26
Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Aug 23
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

Jul 16
Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Apr 18
NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Jan 10
We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

NeoGenomics: Market Punishment Continues, But Looks Justified

Sep 30

NeoGenomics grants CEO restricted shares, stock options

Aug 17

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

Aug 10
Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

NeoGenomics rises ~14% on strong Q2 result

Aug 09

NeoGenomics gets new CEO

Jul 21

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

Jun 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Apr 22
Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Neogenomics: Poor Performance, CEO Departure Create Downward Share Price Spiral

Apr 08

Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching

Feb 11
Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching

Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?

Jan 07
Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?

NeoGenomics: Gambling On Growth

Dec 16

Shareholder Returns

NEOUS HealthcareUS Market
7D-8.0%-1.0%-2.7%
1Y-20.3%-10.2%23.4%

Return vs Industry: NEO underperformed the US Healthcare industry which returned -10.2% over the past year.

Return vs Market: NEO underperformed the US Market which returned 23.4% over the past year.

Price Volatility

Is NEO's price volatile compared to industry and market?
NEO volatility
NEO Average Weekly Movement5.9%
Healthcare Industry Average Movement7.6%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: NEO has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: NEO's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20012,100Chris Smithwww.neogenomics.com

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.

NeoGenomics, Inc. Fundamentals Summary

How do NeoGenomics's earnings and revenue compare to its market cap?
NEO fundamental statistics
Market capUS$2.11b
Earnings (TTM)-US$77.73m
Revenue (TTM)US$644.12m

3.3x

P/S Ratio

-27.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NEO income statement (TTM)
RevenueUS$644.12m
Cost of RevenueUS$363.69m
Gross ProfitUS$280.43m
Other ExpensesUS$358.16m
Earnings-US$77.73m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.61
Gross Margin43.54%
Net Profit Margin-12.07%
Debt/Equity Ratio59.5%

How did NEO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 00:26
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NeoGenomics, Inc. is covered by 29 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bruce JacksonBenchmark Company
Raymond MyersBenchmark Company
Derik de BruinBofA Global Research